New Stock News | Haina Medical Hong Kong Stock IPO Prospectus Invalid

According to the Securities Times APP, the Hong Kong stock prospectus submitted by Nanjing Hanayi Pharmaceutical Technology Co., Ltd. (referred to as Hanayi Pharmaceutical) on November 7, 2025, will expire after 6 months on May 7, 2026. China International Capital Corporation acted as its exclusive sponsor when submitting the application.